Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 11 May 2024
Reviewer's report:
Thanks to the author for revising this manuscript according to my comments, and all my concerns
have been appropriately addressed. It’s a novel study to evaluate Vonoprazan and Tegoprazan
for Gastroesophageal Reflux Disease Treatment in Chinese Healthcare by using EVIDEM
Framework Analysis, which was the first time used in Chinese Healthcare. However, it is worth
noting that there is a lack of literature on the direct comparison of the efficacy of Vonoprazan and
Tegoprazan. As a result, the effects of the two drugs can only be reflected through the comparison
with PPI, which may affect the quality of the "Comparative outcomes of the intervention matrix".
In addition, The authors included fewer Chinese studies in the "Comparative outcomes of the
intervention matrix", in which the primary objective of this study was to evaluate the efficacy
of VPZ and TPZ in the treatment of GERD in Chinese healthcare facilities, this further reduced
the persuasiveness of the results. To address the above shortcomings, The author expanded the
literature search range to ensure that all relevant literature was included in the development of
the evidence matrix, and all experts were carefully screened to ensure that they had sufficient
insight into the relevant fields. The double-blind approach was also used to control the subjective
factors and minimize bias in the evaluation process. At the same time, the authors provided
a comprehensive overview of the research methodology, including a search formula for each
database to ensure the study's reproducibility. Overall, after this time revision, the authors have
elaborated the research process and methodology, as well as provided insightful discussion
of the results, which I believe meets the criteria for publication. It is important to highlight
that the EVIDEM Framework Analysis has the potential capability to assess the utilization of
pertinent pharmaceuticals within Chinese healthcare facilities. I am eagerly awaiting the author's
forthcoming study, which will incorporate the latest studies and utilize novel methodologies to
minimize the potential bias.
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 11 May 2024
Reviewer's report:
Thanks to the author for revising this manuscript according to my comments, and all my concerns
have been appropriately addressed. It’s a novel study to evaluate Vonoprazan and Tegoprazan
for Gastroesophageal Reflux Disease Treatment in Chinese Healthcare by using EVIDEM
Framework Analysis, which was the first time used in Chinese Healthcare. However, it is worth
noting that there is a lack of literature on the direct comparison of the efficacy of Vonoprazan and
Tegoprazan. As a result, the effects of the two drugs can only be reflected through the comparison
with PPI, which may affect the quality of the "Comparative outcomes of the intervention matrix".
In addition, The authors included fewer Chinese studies in the "Comparative outcomes of the
intervention matrix", in which the primary objective of this study was to evaluate the efficacy
of VPZ and TPZ in the treatment of GERD in Chinese healthcare facilities, this further reduced
the persuasiveness of the results. To address the above shortcomings, The author expanded the
literature search range to ensure that all relevant literature was included in the development of
the evidence matrix, and all experts were carefully screened to ensure that they had sufficient
insight into the relevant fields. The double-blind approach was also used to control the subjective
factors and minimize bias in the evaluation process. At the same time, the authors provided
a comprehensive overview of the research methodology, including a search formula for each
database to ensure the study's reproducibility. Overall, after this time revision, the authors have
elaborated the research process and methodology, as well as provided insightful discussion
of the results, which I believe meets the criteria for publication. It is important to highlight
that the EVIDEM Framework Analysis has the potential capability to assess the utilization of
pertinent pharmaceuticals within Chinese healthcare facilities. I am eagerly awaiting the author's
forthcoming study, which will incorporate the latest studies and utilize novel methodologies to
minimize the potential bias.
Please review this paper.
user
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 4 Date: 11 May 2024
Reviewer's report:
Thanks to the author for revising this manuscript according to my comments, and all my concerns
have been appropriately addressed. It’s a novel study to evaluate Vonoprazan and Tegoprazan
for Gastroesophageal Reflux Disease Treatment in Chinese Healthcare by using EVIDEM
Framework Analysis, which was the first time used in Chinese Healthcare. However, it is worth
noting that there is a lack of literature on the direct comparison of the efficacy of Vonoprazan and
Tegoprazan. As a result, the effects of the two drugs can only be reflected through the comparison
with PPI, which may affect the quality of the "Comparative outcomes of the intervention matrix".
In addition, The authors included fewer Chinese studies in the "Comparative outcomes of the
intervention matrix", in which the primary objective of this study was to evaluate the efficacy
of VPZ and TPZ in the treatment of GERD in Chinese healthcare facilities, this further reduced
the persuasiveness of the results. To address the above shortcomings, The author expanded the
literature search range to ensure that all relevant literature was included in the development of
the evidence matrix, and all experts were carefully screened to ensure that they had sufficient
insight into the relevant fields. The double-blind approach was also used to control the subjective
factors and minimize bias in the evaluation process. At the same time, the authors provided
a comprehensive overview of the research methodology, including a search formula for each
database to ensure the study's reproducibility. Overall, after this time revision, the authors have
elaborated the research process and methodology, as well as provided insightful discussion
of the results, which I believe meets the criteria for publication. It is important to highlight
that the EVIDEM Framework Analysis has the potential capability to assess the utilization of
pertinent pharmaceuticals within Chinese healthcare facilities. I am eagerly awaiting the author's
forthcoming study, which will incorporate the latest studies and utilize novel methodologies to
minimize the potential bias.
assistant